Liraglutide vs Semaglutide: GLP-1 Agonist Comparison for Weight Loss and Diabetes | Peptpedia
This comprehensive analysis compares Liraglutide and Semaglutide based on peer-reviewed clinical research, examining their mechanisms of action, efficacy data, and safety profiles. For complete individual peptide profiles, visit the dedicated research pages linked above.
Semaglutide demonstrates superior weight loss efficacy compared to Liraglutide in both clinical trial data and head-to-head comparisons, with once-weekly Semaglutide 2.4 mg (Wegovy) producing approximately 15% body weight reduction versus 5-8% for once-daily Liraglutide 3.0 mg (Saxenda). Both are FDA-approved GLP-1 receptor agonists with established cardiovascular safety profiles. Semaglutide's longer half-life (7 days vs ~13 hours for Liraglutide) enables once-weekly dosing, improving adherence.
Chemical Identity
Side-by-Side Comparison
| Property | Liraglutide | Semaglutide |
|---|---|---|
| Drug Class | GLP-1 Receptor Agonist | GLP-1 Receptor Agonist |
| Brand Names | Victoza (T2D), Saxenda (Obesity) | Ozempic (T2D), Wegovy (Obesity) |
| Dosing Frequency | Once daily subcutaneous | Once weekly subcutaneous |
| Obesity Max Dose | 3.0 mg/day | 2.4 mg/week |
| Half-Life | ~13 hours | ~7 days |
| Weight Loss Efficacy | 5–8% body weight (Saxenda trials) | ~15% body weight (STEP 1) |
| GLP-1 Homology | 97% to native GLP-1 | 94% to native GLP-1 |
| Cardiovascular Trial | LEADER (21% MACE reduction) | SUSTAIN-6, SOUL (26% MACE reduction) |
| FDA Approval (Obesity) | Saxenda (2014) | Wegovy (2021) |
Mechanism of Action: Similarities and Differences
Both Liraglutide and Semaglutide are acylated GLP-1 analogs engineered to resist DPP-4 degradation through fatty acid side chains that enable albumin binding. Liraglutide is a once-daily GLP-1 analog with 97% sequence homology to native GLP-1, using a C-16 fatty acid chain for albumin binding. Its shorter half-life (~13 hours) requires daily injection but allows faster dose adjustments.
Semaglutide uses a C-18 fatty diacid chain with a modified spacer, achieving ~94% sequence homology and a ~7-day half-life through enhanced albumin binding and reduced renal clearance. Both compounds activate GLP-1 receptors in pancreatic beta-cells, the hypothalamus, and the gastrointestinal tract through identical downstream signaling: Gs-mediated cAMP elevation driving insulin secretion and satiety.
Weight Loss Efficacy: Clinical Trial Data
The SCALE Obesity and Prediabetes trial (Liraglutide 3.0 mg, n=3,731) demonstrated 5.6–8.0% body weight reduction at 56 weeks versus placebo. The STEP 1 trial (Semaglutide 2.4 mg, n=1,961) demonstrated 14.9% body weight reduction at 68 weeks. No head-to-head trial has directly compared the two agents for weight loss as of 2026.
The superior efficacy of Semaglutide is attributed to its longer receptor engagement (continuous receptor occupation with once-weekly dosing versus peak-and-trough profile with once-daily Liraglutide) and potentially its more potent central satiety signaling despite slightly lower receptor homology.
Frequently Asked Questions
Research Citations
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer X, Astrup A, Fujioka K, et al. (2015). New England Journal of Medicine
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, et al. (2021). New England Journal of Medicine